Related Experiment Video
Updated: May 25, 2025

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
One-Year Mortality and Hospital Readmission in Survivors of COVID-19 Critical Illness-A Population-Based Cohort Study
Shannon M Fernando1,2, Danial Qureshi1,3,4,5, Zharmaine Ante4
1Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Objectives:
To evaluate 1-year outcomes (mortality, and recurrent hospital and ICU readmission) in adult survivors of COVID-19 critical illness compared with survivors of critical illness from non-COVID-19 pneumonia.
Design:
Population-based retrospective observational cohort study.
Setting:
Province of Ontario, Canada.
Patients:
Six thousand ninety-eight consecutive adult patients (≥ 18 yr old) from 102 centers, admitted to ICU with COVID-19 (from January 1, 2020, to March 31, 2022), and surviving to hospital discharge.
Interventions:
None.
Measurements And Main Results:
The primary outcome was 1-year mortality. We also evaluated the number of emergency department (ED) visits, hospital readmissions, and ICU readmissions over this same time period. We compared patients using overlap propensity score-weighted, cause-specific proportional hazard models. Mean age was 59.6 years and 38.5% were female. Of these patients, 1610 (26.4%) and 375 (6.1%) were readmitted to hospital and ICU, respectively, and 917 (15.0%) died within 1 year. Compared with survivors of critical illness from non-COVID-19 pneumonia ( n = 2568), those who survived COVID-19 critical illness had a lower risk of ED visit (hazard ratio [HR], 0.65 [95% CI, 0.60-0.71]), hospital readmission (HR, 0.56 [95% CI, 0.51-0.62]), ICU readmission (HR, 0.44 [95% CI, 0.37-0.53]), and mortality (HR, 0.67 [95% CI, 0.58-0.78]) within 1 year.
Conclusions:
Risk of ED visit, hospital readmission, ICU readmission, and mortality within 1 year of discharge among survivors of COVID-19 critical illness was lower than survivors of critical illness from non-COVID-19 pneumonia.
More Related Videos
Related Concept Videos
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Comparing the Survival Analysis of Two or More Groups
Cancer Survival Analysis
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Kaplan-Meier Approach
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

